Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) said it received a further 602.5 million yuan from MediLink Therapeutics as part of a licensing settlement involving YL201, according to a Friday filing with the Hong Kong bourse.
The firm said it had so far received 702.7 million yuan from MediLink Therapeutics.
Sichuan Kelun-Biotech previously pursued criminal proceedings against MediLink Therapeutics over allegations the firm misappropriated its trade secrets.
Both sides then reached a settlement under an out-licensing deal covering several drugs, including YL201.